{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T19:02:11Z","timestamp":1767034931673},"reference-count":51,"publisher":"American Medical Association (AMA)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"DOI":"10.1001\/jamapediatrics.2020.2422","type":"journal-article","created":{"date-parts":[[2020,6,6]],"date-time":"2020-06-06T08:23:17Z","timestamp":1591431797000},"page":"e202422","source":"Crossref","is-referenced-by-count":33,"title":["Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019"],"prefix":"10.1001","volume":"174","author":[{"given":"Anil R.","family":"Maharaj","sequence":"first","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huali","family":"Wu","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph P.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Balevic","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi D.","family":"Hornik","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"},{"name":"Department of Pharmacy, Duke University Medical Center, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Brian","family":"Smith","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"University of North Carolina Eshelman School of Pharmacy, Division of Pharmacotherapy and Experimental Therapeutics, University of North Carolina at Chapel Hill"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanecia O.","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Daniel K.","family":"Benjamin","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Cohen-Wolkowiez","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Durham, North Carolina"},{"name":"Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Best Pharmaceuticals for Children Act\u2013Pediatric Trials Network Steering Committee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","published-online":{"date-parts":[[2020,10,5]]},"reference":[{"key":"poi200041r1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0702","article-title":"Epidemiology of COVID-19 among children in China.","author":"Dong","year":"2020","journal-title":"Pediatrics"},{"issue":"17","key":"poi200041r2","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1056\/NEJMc2005073","article-title":"SARS-CoV-2 infection in children.","volume":"382","author":"Lu","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"poi200041r3","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","article-title":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia.","volume":"382","author":"Li","year":"2020","journal-title":"N Engl J Med"},{"issue":"10223","key":"poi200041r4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"poi200041r5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV).","volume":"19","author":"Li","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"poi200041r6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105933","article-title":"Arguments in favour of remdesivir for treating SARS-CoV-2 infections.","volume":"55","author":"Ko","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"3","key":"poi200041r7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105923","article-title":"Chloroquine for the 2019 novel coronavirus SARS-CoV-2.","volume":"55","author":"Colson","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"poi200041r8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1001\/archinte.159.2.167","article-title":"Treatment of Q fever endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin or hydroxychloroquine.","volume":"159","author":"Raoult","year":"1999","journal-title":"Arch Intern Med"},{"issue":"9","key":"poi200041r9","doi-asserted-by":"publisher","first-page":"2845","DOI":"10.1021\/jm0601856","article-title":"Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities.","volume":"49","author":"Biot","year":"2006","journal-title":"J Med Chem"},{"key":"poi200041r10","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).","author":"Yao","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"poi200041r11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1111\/bcp.1988.26.issue-3","article-title":"A dose-ranging study of the pharmacokinetics of hydroxy-chloroquine following intravenous administration to healthy volunteers.","volume":"26","author":"Tett","year":"1988","journal-title":"Br J Clin Pharmacol"},{"key":"poi200041r12","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.","volume":"5","author":"Furst","year":"1996","journal-title":"Lupus"},{"issue":"4","key":"poi200041r13","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1128\/AAC.00339-08","article-title":"Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax.","volume":"53","author":"Lim","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"poi200041r14","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00399-20","article-title":"Compounds with therapeutic potential against novel respiratory 2019 coronavirus.","volume":"64","author":"Martinez","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"7594","key":"poi200041r15","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"issue":"2","key":"poi200041r16","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease.","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio"},{"issue":"3","key":"poi200041r18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res"},{"issue":"2","key":"poi200041r19","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1208\/s12248-013-9451-0","article-title":"A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.","volume":"15","author":"Maharaj","year":"2013","journal-title":"AAPS J"},{"key":"poi200041r20","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2014.45","article-title":"Physiologically based pharmacokinetic modeling and simulation in pediatric drug development.","volume":"3","author":"Maharaj","year":"2014","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"1","key":"poi200041r21","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and Drug Administration\u2019s Office of Clinical Pharmacology.","volume":"108","author":"Grimstein","year":"2019","journal-title":"J Pharm Sci"},{"issue":"2","key":"poi200041r22","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/jcph.1310","article-title":"A comparative study between allometric scaling and physiologically based pharmacokinetic modeling for the prediction of drug clearance from neonates to adolescents.","volume":"59","author":"Mahmood","year":"2019","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"poi200041r23","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s10928-015-9417-1","article-title":"Reporting guidelines for population pharmacokinetic analyses.","volume":"42","author":"Dykstra","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"poi200041r26","first-page":"S65","article-title":"Simple, automatic noncompartmental analysis: the PKNCA R package.","volume":"42","author":"Denney","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"i06","key":"poi200041r27","article-title":"zoo: S3 infrastructure for regular and irregular time series.","volume":"14","author":"Grothendieck","year":"2005","journal-title":"J Stat Softw"},{"issue":"5","key":"poi200041r28","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1038\/clpt.2012.19","article-title":"Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.","volume":"91","author":"Leong","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"poi200041r29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/jcph.1994.34.issue-11","article-title":"Hematologic disposition of hydroxychloroquine enantiomers.","volume":"34","author":"Brocks","year":"1994","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"poi200041r30","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/BF00315548","article-title":"Plasma protein binding of the enantiomers of hydroxychloroquine and metabolites.","volume":"44","author":"McLachlan","year":"1993","journal-title":"Eur J Clin Pharmacol"},{"issue":"7","key":"poi200041r31","doi-asserted-by":"publisher","first-page":"3091","DOI":"10.1128\/AAC.01835-10","article-title":"Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine.","volume":"55","author":"M\u00fcller","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"poi200041r32","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40744-015-0012-0","article-title":"Pharmacokinetics and bioequivalence study of hydroxychloroquine sulfate tablets in Chinese healthy volunteers by LC-MS\/MS.","volume":"2","author":"Fan","year":"2015","journal-title":"Rheumatol Ther"},{"issue":"2","key":"poi200041r33","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/jps.2600810211","article-title":"Bioavailability of hydroxychloroquine tablets assessed with deconvolution techniques.","volume":"81","author":"Tett","year":"1992","journal-title":"J Pharm Sci"},{"issue":"5-6","key":"poi200041r34","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00228-003-0636-9","article-title":"Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.","volume":"59","author":"Li","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"poi200041r35","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/rheumatology\/33.3.235","article-title":"Bioavailability of hydroxychloroquine tablets in patients with rheumatoid arthritis.","volume":"33","author":"McLachlan","year":"1994","journal-title":"Br J Rheumatol"},{"issue":"5","key":"poi200041r36","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/bcp.1993.36.issue-5","article-title":"Absorption and in vivo dissolution of hydroxycholoroquine in fed subjects assessed using deconvolution techniques.","volume":"36","author":"McLachlan","year":"1993","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"poi200041r37","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1111\/bcp.1989.27.issue-6","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers.","volume":"27","author":"Tett","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"poi200041r38","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/cpt.v106.5","article-title":"A comprehensive analysis of ontogeny of renal drug transporters: mRNA analyses, quantitative proteomics, and localization.","volume":"106","author":"Cheung","year":"2019","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"poi200041r39","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10928-007-9053-5","article-title":"Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.","volume":"34","author":"Willmann","year":"2007","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"2","key":"poi200041r42","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1021\/tx200479k","article-title":"Quantifying processes determining the free concentration of phenanthrene in Basal cytotoxicity assays.","volume":"25","author":"Kramer","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"3","key":"poi200041r43","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0194880","article-title":"Testing therapeutics in cell-based assays: factors that influence the apparent potency of drugs.","volume":"13","author":"Postnikova","year":"2018","journal-title":"PLoS One"},{"key":"poi200041r44","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discov"},{"key":"poi200041r45","article-title":"COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression.","author":"Zhou","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"poi200041r46","doi-asserted-by":"crossref","DOI":"10.1111\/cts.12797","article-title":"Hydroxychloroquine for treatment of SARS-CoV-2 infection? improving our confidence in a model-based approach to dose selection.","author":"Arnold","year":"2020","journal-title":"Clin Transl Sci"},{"issue":"4","key":"poi200041r47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40262-018-0712-z","article-title":"Pharmacokinetics of hydroxychloroquine in pregnancies with rheumatic diseases.","volume":"58","author":"Balevic","year":"2019","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"poi200041r48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1097\/FTD.0000000000000261","article-title":"Population pharmacokinetics of hydroxychloroquine in Japanese patients with cutaneous or systemic lupus erythematosus.","volume":"38","author":"Morita","year":"2016","journal-title":"Ther Drug Monit"},{"issue":"5","key":"poi200041r49","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1097\/FTD.0000000000000543","article-title":"Age- and bodyweight-dependent allometric exponent model for scaling clearance and maintenance dose of theophylline from neonates to adults.","volume":"40","author":"Tegenge","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1","key":"poi200041r50","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/art.39402","article-title":"Association of polymorphisms of cytochrome P450 2D6 with blood hydroxychloroquine levels in patients with systemic lupus erythematosus.","volume":"68","author":"Lee","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"poi200041r51","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1124\/dmd.31.6.748","article-title":"In vitro metabolism of chloroquine: identification of CYP2C8, CYP3A4, and CYP2D6 as the main isoforms catalyzing N-desethylchloroquine formation.","volume":"31","author":"Projean","year":"2003","journal-title":"Drug Metab Dispos"},{"year":"2009","author":"Wickham","key":"poi200041r24"},{"key":"poi200041r17","unstructured":"European Medicines Agency (EMA). Summary on compassionate use: Remdesivir Gilead (Procedure No. EMEA\/H\/K\/5622\/CU). Published April 3, 2020. Accessed April 14, 2020. https:\/\/www.ema.europa.eu\/en\/documents\/other\/summary-compassionate-use-remdesivir-gilead_en.pdf"},{"key":"poi200041r25","unstructured":"Wilke? CO. cowplot: Streamlined Plot Theme and Plot Annotations for 'ggplot2'. rdrr.io website. Accessed April 14, 2020. https:\/\/rdrr.io\/cran\/cowplot\/"},{"key":"poi200041r40","unstructured":"Sciensano Epidemiology of Infectious Disease. Interim clinical guidance for adults with suspected or confirmed COVID-19 in Belgium, Version 7. sciensano website. Published April 7, 2020. Accessed April 14, 2020. https:\/\/epidemio.wiv-isp.be\/ID\/Documents\/Covid19\/COVID-19_InterimGuidelines_Treatment_ENG.pdf?"},{"key":"poi200041r41","unstructured":"Michigan Medicine, University of Michigan. Inpatient guidance for treatment of COVID-19 in adults and children. Michigan Medicine, University of Michigan website. Accessed April 14, 2020. http:\/\/www.med.umich.edu\/asp\/pdf\/adult_guidelines\/COVID-19-treatment.pdf"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2767020\/jamapediatrics_maharaj_2020_oi_200041_1601481571.94953.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,5]],"date-time":"2020-10-05T15:03:10Z","timestamp":1601910190000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2767020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,5]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2020.2422","relation":{},"ISSN":["2168-6203"],"issn-type":[{"type":"print","value":"2168-6203"}],"subject":[],"published":{"date-parts":[[2020,10,5]]}}}